DK0886679T3 - Parakoppevira indeholdende fremmed DNA, fremstilling heraf og deres anvendelse i vacciner - Google Patents

Parakoppevira indeholdende fremmed DNA, fremstilling heraf og deres anvendelse i vacciner

Info

Publication number
DK0886679T3
DK0886679T3 DK97904453T DK97904453T DK0886679T3 DK 0886679 T3 DK0886679 T3 DK 0886679T3 DK 97904453 T DK97904453 T DK 97904453T DK 97904453 T DK97904453 T DK 97904453T DK 0886679 T3 DK0886679 T3 DK 0886679T3
Authority
DK
Denmark
Prior art keywords
vaccines
preparation
paracobal
foreign dna
containing foreign
Prior art date
Application number
DK97904453T
Other languages
English (en)
Inventor
Norbert Schmeer
Walter Strube
Mathias Buettner
Hans-Joachim Rziha
Original Assignee
Bayer Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19639601A external-priority patent/DE19639601A1/de
Application filed by Bayer Healthcare Ag filed Critical Bayer Healthcare Ag
Application granted granted Critical
Publication of DK0886679T3 publication Critical patent/DK0886679T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24211—Parapoxvirus, e.g. Orf virus
    • C12N2710/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24211—Parapoxvirus, e.g. Orf virus
    • C12N2710/24241—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24243—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK97904453T 1996-02-28 1997-02-17 Parakoppevira indeholdende fremmed DNA, fremstilling heraf og deres anvendelse i vacciner DK0886679T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19607458 1996-02-28
DE19639601A DE19639601A1 (de) 1996-02-28 1996-09-26 Parapockenviren, die Fremd-DNA enthalten, ihre Herstellung und ihre Verwendung in Impfstoffen
PCT/EP1997/000729 WO1997032029A1 (de) 1996-02-28 1997-02-17 Parapockenviren, die fremd-dna enthalten, ihre herstellung und ihre verwendung in impfstoffen

Publications (1)

Publication Number Publication Date
DK0886679T3 true DK0886679T3 (da) 2007-09-24

Family

ID=26023280

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97904453T DK0886679T3 (da) 1996-02-28 1997-02-17 Parakoppevira indeholdende fremmed DNA, fremstilling heraf og deres anvendelse i vacciner

Country Status (19)

Country Link
US (1) US6365393B1 (da)
EP (1) EP0886679B1 (da)
JP (1) JP2000507092A (da)
CN (1) CN1217027A (da)
AT (1) ATE364090T1 (da)
AU (1) AU718141B2 (da)
BR (1) BR9707785A (da)
CA (1) CA2247336C (da)
DE (1) DE59712852D1 (da)
DK (1) DK0886679T3 (da)
ES (1) ES2287949T3 (da)
HU (1) HUP9901035A3 (da)
IL (1) IL125797A0 (da)
NO (1) NO983946L (da)
NZ (1) NZ331556A (da)
PL (1) PL190401B1 (da)
SK (1) SK120098A3 (da)
TR (1) TR199801702T2 (da)
WO (1) WO1997032029A1 (da)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0904393A4 (en) * 1996-03-29 1999-09-08 Univ Otago PARAPOXVIRUS VECTORS
DE69939374D1 (de) * 1998-03-17 2008-10-02 Genentech Inc Zu vegf und bmp1 homologe polypeptide
AU775956B2 (en) * 1998-11-02 2004-08-19 Otago Innovation Limited Vascular endothelial growth factor-like protein from ORF virus NZ2 binds and activates mammalian VEGF receptor-2
GB2381454B8 (en) * 2000-07-11 2007-10-23 Aicuris Gmbh & Co Kg Use of strains of Parapoxvirus ovis for producing antiviral medicaments and medicaments against cancer
US6752995B2 (en) * 2002-04-15 2004-06-22 Board Of Regents, The University Of Texas System Nucleic acid and polypeptide sequences useful as adjuvants
US6844000B2 (en) 2001-12-07 2005-01-18 Bayer Pharmaceuticals Corporation Use of Parapox B2L protein to treat cancer and modify immune responses
CA2573204C (en) * 2004-07-13 2011-09-20 Aicuris Gmbh & Co. Kg Parapoxviruses in combination with other antiviral agents for the treatment of hiv/aids
CA2795308A1 (en) * 2010-04-29 2011-11-03 Riemser Arzneimittel Ag Parapoxvirus expressing the vp60 major capsid protein of the rabbit haemorrhagic disease virus
BR112012029633A8 (pt) * 2010-05-21 2017-12-05 Ah Usa 42 Llc Vetores do parapoxvírus contendo antígeno do vírus da raiva.
RU2013102413A (ru) * 2010-07-20 2014-08-27 ЭйЭйч ЮЭсЭй 42 ЭлЭлСи Парапоксвирусные векторы
EP2875041A2 (en) 2012-07-19 2015-05-27 Zoetis LLC Bovine influenza c virus compositions
AU2013295770A1 (en) 2012-07-27 2015-01-29 Zoetis Services Llc Tick toxin compositions
DE102015111756A1 (de) * 2015-07-20 2017-01-26 Eberhard Karls Universität Tübingen Medizinische Fakultät Rekombinanter Orf-Virus-Vektor
EP4137152A1 (en) 2015-08-14 2023-02-22 Zoetis Services LLC Mycoplasma bovis compositions
EP3432922B1 (en) 2016-03-21 2020-02-19 South Dakota Board of Regents Orf virus-based platform for vaccine delivery
JP2021516957A (ja) * 2018-03-07 2021-07-15 トランジェーヌＴｒａｎｓｇｅｎｅ パラポックスウイルスベクター
WO2024062098A1 (en) 2022-09-23 2024-03-28 Transgene Recombinant pseudocowpox virus encoding an interleukin-12

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4405841C1 (de) * 1994-02-23 1995-01-05 Mayr Anton Prof Dr Med Vet Dr Multipotente Paramunitätsinducer auf der Basis von Kombinationen von Pockenviruskomponenten, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
AU694519B2 (en) * 1994-04-29 1998-07-23 Immuno Aktiengesellschaft Recombinant poxviruses with foreign polynucleotides in essential regions

Also Published As

Publication number Publication date
EP0886679B1 (de) 2007-06-06
HUP9901035A2 (hu) 1999-07-28
CA2247336A1 (en) 1997-09-04
BR9707785A (pt) 1999-07-27
TR199801702T2 (xx) 1998-12-21
PL190401B1 (pl) 2005-12-30
WO1997032029A1 (de) 1997-09-04
US6365393B1 (en) 2002-04-02
IL125797A0 (en) 1999-04-11
CN1217027A (zh) 1999-05-19
AU1725797A (en) 1997-09-16
ES2287949T3 (es) 2007-12-16
NO983946L (no) 1998-10-22
HUP9901035A3 (en) 2001-01-29
DE59712852D1 (de) 2007-07-19
SK120098A3 (en) 1999-03-12
PL328870A1 (en) 1999-03-01
JP2000507092A (ja) 2000-06-13
NZ331556A (en) 2000-05-26
ATE364090T1 (de) 2007-06-15
NO983946D0 (no) 1998-08-27
AU718141B2 (en) 2000-04-06
CA2247336C (en) 2008-06-17
EP0886679A1 (de) 1998-12-30

Similar Documents

Publication Publication Date Title
DK0886679T3 (da) Parakoppevira indeholdende fremmed DNA, fremstilling heraf og deres anvendelse i vacciner
ATE404220T1 (de) Rekombinierte pockenvirus-tollwut zusammensetzung und kombinierte zusammensetzungen und deren verwendung
BRPI9912663B1 (pt) vacina contra cáncer e polipeptìdeo.
ATE286067T1 (de) Hcv hüllproteine partikel : verwendung für therapeutische impfung
ATE468858T1 (de) Chimäre impfstoffe gegen flaviviren
SI1554301T1 (sl) VAKCINA ZA DENGO, KI VSEBUJE SKUPNO DELECIJO 30 NUKLEOTIDOV V 3ĹľUTR TIPOV 1 IN 2 DENGE
NO20091761L (no) Viruskapsomervaksine, fremgangsmate for fremstilling samt anvendelse derav
DE69833649D1 (de) Ef-1-alpha transkriptionsregulatorische dna aus hamster
DE69836588D1 (de) Tuberkulose impfstoff
IL181695A0 (en) Methods for cultivating cells and propagating viruses
MX9708426A (es) Polipeptido hk2 de variante estable.
DE69836520D1 (de) Clostridium perfringens Impfstoff
YU36698A (sh) Parapoks-virusi koji sadrže stranu dnk, njihovo dobijanje i njihova primena u vakcinama
DE69840637D1 (de) Zusammensetzungen zur steigerung der effizienz von impfstoffen unter verwendung von chemokinen
DE60131975D1 (de) Anwendung des herpes simplex virus glykoproteins-d zur unterdrückung von immunantworten
ATE233321T1 (de) Verbesserungen in der herstellung von proteinen in wirtszellen
WO1998024912A3 (en) Recombinant plague vaccine
NZ511168A (en) Recombinant CELO virus and CELO virus DNA
DE68925356D1 (de) Nicht-zurückmutierende RNA-Viren